This observation could further explain the therapeutic efficacy of the COMBO treatment with 2 Gy + Tag-Th1 + dual PD-L1/Lag-3 immune checkpoint blockade in late-stage RIP1-Tag2 mice with metastatic insular carcinomas, while treatment with 2 Gy + Tag-Th1 cells alone was not efficient 8. The gene discussed is LAG3; the disease is poorly differentiated thyroid gland carcinoma.